CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Intravenous lidocaine and ketamine infusions for chronic pain

This policy governs coverage for intravenous (IV) infusion of anesthetics (ketamine or lidocaine) when used to treat chronic pain conditions, chronic daily headache, and fibromyalgia for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyIntravenous lidocaine and ketamine infusions for chronic pain

Policy CodePolicy N/A

Change TypeNo material change

Effective DateMay 23, 2011

Next Review DateN/A

Key ActionDo not submit claims for IV ketamine or lidocaine for chronic pain as they are considered not medically necessary.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not medically necessaryCoverage stance for IV ketamine or lidocaine for chronic pain

Off-labelOff-label use

Unlisted CPTCPT guidance

2011Policy effective (original)

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Not medically necessary

Covered when ALL of the following are met:

Default coverage determination: IV infusion of anesthetics (eg, ketamine or lidocaine) for treatment of chronic pain disorders (including chronic neuropathic pain, chronic daily headache, and fibromyalgia) is considered not medically necessary due to insufficient evidence of health outcome benefit.

Based on evidence summarized in background; temporary relief noted in some studies but limited durability and safety concerns.

This policy notes that use of intravenous (IV) ketamine or lidocaine for chronic pain indications is an off-label application of these agents. IV lidocaine is FDA-approved for arrhythmias and local anesthesia but not for chronic pain, and IV ketamine’s FDA indications are limited to anesthesia-related uses; neither agent is FDA-approved for chronic pain treatment. The policy therefore treats these indications cautiously and clarifies they are not within the labeled regulatory scope.

The policy covers IV infusion of anesthetics such as ketamine and lidocaine specifically in the context of treating chronic pain conditions including chronic neuropathic pain, chronic daily headache, and fibromyalgia. For these chronic pain indications the policy concludes that IV infusion of these anesthetics is not medically necessary due to insufficient evidence of health outcome benefit. As noted, these infusions for chronic pain are off-label uses of the medicines involved.

Provider Actions and Operational Notes

Prior Authorization

Prior authorization is not required for intravenous infusion of anesthetics (e.g., ketamine or lidocaine) for chronic pain under this policy.

Note

Conservative Treatment Context

Conservative therapies are generally considered first-line for chronic neuropathic pain and fibromyalgia. Treatments commonly used include neuropathic pain medications (e.g., pregabalin), non-narcotic analgesics, low-dose antidepressants, sympathetic ganglion blocks, and oral agents such as mexiletine or oral ketamine when appropriate. IV courses of ketamine or lidocaine have been studied and may provide temporary symptom relief in some patients, but evidence is insufficient regarding long-term benefit and safety for repeat courses.

Documentation Required

Benefit / Eligibility Verification

Verify the member's benefits and eligibility prior to providing services. Coverage is determined by the member's subscriber agreement, member certificate, or employer agreement and those documents supersede this policy. For member-specific information, contact the provider call center.

Denial Risk

Not Medically Necessary — Denial Risk

Intravenous infusion of anesthetics for chronic pain (including chronic neuropathic pain, chronic daily headache, and fibromyalgia) is considered not medically necessary under BlueCHiP for Medicare and Commercial Products due to insufficient evidence. Denial of coverage is possible for these indications.

Affected indications: chronic neuropathic pain, chronic daily headache, fibromyalgia, CRPS and other chronic pain conditions

Background and Evidence Summary

Intravenous ketamine and lidocaine have been investigated in clinical settings for a variety of chronic pain syndromes, including neuropathic pain, chronic daily headache disorders, and fibromyalgia. Ketamine acts as an N‑methyl‑D‑aspartate (NMDA) receptor antagonist with dissociative anesthetic properties and notable adverse effects; lidocaine blocks voltage‑gated sodium channels and is associated with potential cardiac risks. The published evidence reports occasional short‑term symptom relief for some patients, but overall data are limited in quality and durability of benefit, and safety concerns remain, which contributes to the policy’s determination regarding medical necessity.

Definitions

Chronic daily headache definition

DefinitionA headache disorder that occurs more than 15 days a month for at least 3 months; includes chronic migraine, new daily persistent headache, hemicranias continua, and chronic tension-type headache.

Minimum frequency thresholdMore than 15 days per month for at least 3 months.

Included subtypesChronic migraine; new daily persistent headache; hemicranias continua; chronic tension-type headache.

Neuropathic pain definition

DefinitionPain often disproportionate to the primary triggering injury and may include thermal or mechanical allodynia, dysesthesia, and/or hyperalgesia; symptoms may persist for ≥6 months beyond expected recovery.

Key featuresAllodynia (pain from normally non-painful stimuli), dysesthesia (constant unpleasant/electrical pain), hyperalgesia (exaggerated response to painful stimuli).

Typical durationSymptoms may continue for a period longer (e.g., ≥6 months) than clinically expected after an illness or injury.

MechanismsThought to involve peripheral afferent sensitization, neurogenic inflammation, sympathetic afferent coupling, and central sensitization mediated in part by NMDA receptors.

Testing and Monitoring Requirements